Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Mar 4, 2005
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that Chief Scientific Officer, Dai Chaplin, will present at the 3rd International Symp...

Mar 4, 2005
OXiGENE Announces Sale of $15 Million of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's effective shelf registration statement filed in October 2003. The shares are being sold to certain inst...

Mar 1, 2005
OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2005--OXiGENE, Inc. (NASDAQ:OXGN, XSSE:OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present at Wells Fargo Sec...

Feb 25, 2005
OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 25, 2005--Accomplishments in 2004: Initiated two new clinical oncology trials with CA4P; CA4P now studied in seven clinical oncology trials Initiated a Phase II trial of CA4P...

Feb 22, 2005
OXiGENE to Participate on Distinguished Anti-angiogenesis Panel at BIO CEO & Investor Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 22, 2005--OXiGENE Inc, (NASDAQ: OXGN, SSE: OXGN) today announced that Dai Chaplin, Chief Scientific Officer of OXiGENE, will participate in a focus session entitled "Starving Cancer" at the Biotechnology Industry Organization's CEO & Investor Conference on Thursday, February 24, 2005 9:30 AM. The confe...

Feb 18, 2005
OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference: February 22nd Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), today announced that President and Chief Executive Officer Fred Driscoll will present at Roth Capital Partners 17th Annual OC Conference, at the St. Regis Monarch Beach Resort and Spa in Dana Point, California.. ...

Feb 14, 2005
OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies

Data Presented at International Symposium on Anti-Angiogenic Agents Conference in La JollaWALTHAM, Mass., Feb 14, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN) announced today that Dietmar Siemann, Ph.D., chairman of its scientific advisory boar...

Feb 9, 2005
OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's fourth quarter and full-year 2004 financial results conference call at 10:00 a.m. ET Friday, February 25, 2005. President and Chief Executive Officer Fred Driscoll, Chief Financial Office...

Feb 4, 2005
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science -

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using local administration of Combretastatin A4P (CA4P) in the treatment of a murine model of retinoblastoma. The study reported that a subconjunctival delivery of CA4P, a vascular targeting agent (VTA)...

Jan 7, 2005
OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and certain eye diseases, today announced its corporate goals for 2005. "We believe we are entering 2005 in th...

FirstPrevious
...
34
= add release to Briefcase